Literature DB >> 28616321

Comment on prognostic value of epidermal growth factor receptor mutation subtypes in surgically resected non-small cell lung cancer.

Yujin Kudo1, Yoshihisa Shimada1, Hisashi Saji1,2, Norihiko Ikeda1.   

Abstract

Entities:  

Year:  2017        PMID： 28616321      PMCID： PMC5465144          DOI： 10.21037/jtd.2017.03.62

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  21 in total

1.  Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib.

Authors:  Kendall D Carey; Andrew J Garton; Maria S Romero; Jennifer Kahler; Stuart Thomson; Sarajane Ross; Frances Park; John D Haley; Neil Gibson; Mark X Sliwkowski
Journal:  Cancer Res       Date:  2006-08-15       Impact factor: 12.701

2.  Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.

Authors:  James Chih-Hsin Yang; Yi-Long Wu; Martin Schuler; Martin Sebastian; Sanjay Popat; Nobuyuki Yamamoto; Caicun Zhou; Cheng-Ping Hu; Kenneth O'Byrne; Jifeng Feng; Shun Lu; Yunchao Huang; Sarayut L Geater; Kye Young Lee; Chun-Ming Tsai; Vera Gorbunova; Vera Hirsh; Jaafar Bennouna; Sergey Orlov; Tony Mok; Michael Boyer; Wu-Chou Su; Ki Hyeong Lee; Terufumi Kato; Dan Massey; Mehdi Shahidi; Victoria Zazulina; Lecia V Sequist
Journal:  Lancet Oncol       Date:  2015-01-12       Impact factor: 41.316

3.  Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.

Authors:  David A Eberhard; Bruce E Johnson; Lukas C Amler; Audrey D Goddard; Sherry L Heldens; Roy S Herbst; William L Ince; Pasi A Jänne; Thomas Januario; David H Johnson; Pam Klein; Vincent A Miller; Michael A Ostland; David A Ramies; Dragan Sebisanovic; Jeremy A Stinson; Yu R Zhang; Somasekar Seshagiri; Kenneth J Hillan
Journal:  J Clin Oncol       Date:  2005-07-25       Impact factor: 44.544

4.  Activating mutations within the EGFR kinase domain: a molecular predictor of disease-free survival in resected pulmonary adenocarcinoma.

Authors:  Young Joo Lee; In Kyu Park; Moo-Suk Park; Hye Jin Choi; Byoung Chul Cho; Kyung Young Chung; Se Kyu Kim; Joon Chang; Jin Wook Moon; Hoguen Kim; Sung Ho Choi; Joo-Hang Kim
Journal:  J Cancer Res Clin Oncol       Date:  2009-06-11       Impact factor: 4.553

5.  Prognostic value of EGFR mutations in surgically resected pathological stage I lung adenocarcinoma.

Authors:  Teppei Nishii; Tomoyuki Yokose; Yohei Miyagi; Yataro Daigo; Tetsuya Isaka; Hideyuki Furumoto; Hiroyuki Ito; Shuji Murakami; Tetsuro Kondo; Haruhiro Saito; Fumihiro Oshita; Kouzo Yamada; Shoichi Matsukuma; Haruhiko Nakayama; Munetaka Masuda
Journal:  Asia Pac J Clin Oncol       Date:  2016-06-28       Impact factor: 2.601

6.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

Authors:  Tony S Mok; Yi-Long Wu; Sumitra Thongprasert; Chih-Hsin Yang; Da-Tong Chu; Nagahiro Saijo; Patrapim Sunpaweravong; Baohui Han; Benjamin Margono; Yukito Ichinose; Yutaka Nishiwaki; Yuichiro Ohe; Jin-Ji Yang; Busyamas Chewaskulyong; Haiyi Jiang; Emma L Duffield; Claire L Watkins; Alison A Armour; Masahiro Fukuoka
Journal:  N Engl J Med       Date:  2009-08-19       Impact factor: 91.245

7.  Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma.

Authors:  Takayuki Kosaka; Yasushi Yatabe; Ryoichi Onozato; Hiroyuki Kuwano; Tetsuya Mitsudomi
Journal:  J Thorac Oncol       Date:  2009-01       Impact factor: 15.609

8.  Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma.

Authors:  Jenifer L Marks; Stephen Broderick; Qin Zhou; Dhananjay Chitale; Allan R Li; Maureen F Zakowski; Mark G Kris; Valerie W Rusch; Christopher G Azzoli; Venkatraman E Seshan; Marc Ladanyi; William Pao
Journal:  J Thorac Oncol       Date:  2008-02       Impact factor: 15.609

9.  Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking.

Authors:  K Sugio; H Uramoto; K Ono; T Oyama; T Hanagiri; M Sugaya; Y Ichiki; T So; S Nakata; M Morita; K Yasumoto
Journal:  Br J Cancer       Date:  2006-03-27       Impact factor: 7.640

10.  Differences among lesions with exon 19, exon 21 EGFR mutations and wild types in surgically resected non-small cell lung cancer.

Authors:  Ying Jin; Ming Chen; Xinmin Yu
Journal:  Sci Rep       Date:  2016-08-16       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.